PRELUDE THERAPEUTICS INC Increase (Decrease) in Accounts Payable
PRELUDE THERAPEUTICS INC (PRLD) reported Increase (Decrease) in Accounts Payable of -$2.03 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayable · last filed 2026-08-11
- PRELUDE THERAPEUTICS INC increase (decrease) in accounts payable for the quarter ending 2026-06-30 was -$154.00K.
- PRELUDE THERAPEUTICS INC increase (decrease) in accounts payable for the quarter ending 2026-03-31 was -$1.88M.
- PRELUDE THERAPEUTICS INC increase (decrease) in accounts payable for the quarter ending 2025-12-31 was $1.27M, a 29.78% decline year-over-year.
- PRELUDE THERAPEUTICS INC increase (decrease) in accounts payable for the quarter ending 2025-09-30 was -$2.43M.
- PRELUDE THERAPEUTICS INC increase (decrease) in accounts payable for fiscal 2025 was -$3.92M, a 218.55% decline from fiscal 2024.
- PRELUDE THERAPEUTICS INC increase (decrease) in accounts payable for fiscal 2024 was $3.31M.
- PRELUDE THERAPEUTICS INC increase (decrease) in accounts payable for fiscal 2023 was -$2.27M.
- PRELUDE THERAPEUTICS INC increase (decrease) in accounts payable for fiscal 2022 was -$347.00K, a 108.89% decline from fiscal 2021.
| Period end | Increase (Decrease) in Accounts Payable 3 month | Increase (Decrease) in Accounts Payable 6 month | Increase (Decrease) in Accounts Payable 9 month | Increase (Decrease) in Accounts Payable 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$154.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$2.03M 10-Q · filed 2026-08-11 | -$762.00K derived: sum of 3 quarters · filed 2026-08-11 | -$3.19M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | -$1.88M 10-Q · filed 2026-05-12 | -$608.00K derived: sum of 2 quarters · filed 2026-05-12 | -$3.04M derived: sum of 3 quarters · filed 2026-05-12 | -$3.89M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $1.27M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | -$1.16M derived: sum of 2 quarters · filed 2026-03-10 | -$2.01M derived: sum of 3 quarters · filed 2026-08-11 | -$3.92M 10-K · filed 2026-03-10 |
| 2025-09-30 | -$2.43M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$3.28M derived: sum of 2 quarters · filed 2026-08-11 | -$5.19M 10-Q · filed 2025-11-12 | -$3.38M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | -$850.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$2.76M 10-Q · filed 2026-08-11 | -$950.00K derived: sum of 3 quarters · filed 2026-08-11 | -$1.16M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | -$1.91M 10-Q · filed 2026-05-12 | -$100.00K derived: sum of 2 quarters · filed 2026-05-12 | -$313.00K derived: sum of 3 quarters · filed 2026-05-12 | $764.00K derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $1.81M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $1.60M derived: sum of 2 quarters · filed 2026-03-10 | $2.67M derived: sum of 3 quarters · filed 2026-03-10 | $3.31M 10-K · filed 2026-03-10 |
| 2024-09-30 | -$213.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $864.00K derived: sum of 2 quarters · filed 2025-11-12 | $1.50M 10-Q · filed 2025-11-12 | $1.03M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $1.08M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $1.71M 10-Q · filed 2025-08-14 | $1.24M derived: sum of 3 quarters · filed 2025-08-14 | $771.00K derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $631.00K 10-Q · filed 2025-05-06 | $166.00K derived: sum of 2 quarters · filed 2025-05-06 | -$306.00K derived: sum of 3 quarters · filed 2025-05-06 | -$2.01M derived: sum of 4 quarters · filed 2025-05-06 |
| 2023-12-31 | -$465.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10 | -$937.00K derived: sum of 2 quarters · filed 2025-03-10 | -$2.64M derived: sum of 3 quarters · filed 2025-03-10 | -$2.27M 10-K · filed 2025-03-10 |
| 2023-09-30 | -$472.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | -$2.18M derived: sum of 2 quarters · filed 2024-11-06 | -$1.80M 10-Q · filed 2024-11-06 | -$5.04M derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | -$1.71M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | -$1.33M 10-Q · filed 2024-08-12 | -$4.57M derived: sum of 3 quarters · filed 2024-08-12 | -$842.00K derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | $374.00K 10-Q · filed 2024-05-07 | -$2.87M derived: sum of 2 quarters · filed 2024-05-07 | $865.00K derived: sum of 3 quarters · filed 2024-05-07 | $25.00K derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | -$3.24M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | $491.00K derived: sum of 2 quarters · filed 2024-02-15 | -$349.00K derived: sum of 3 quarters · filed 2024-02-15 | -$347.00K 10-K · filed 2024-02-15 |
| 2022-09-30 | $3.73M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-01 | $2.89M derived: sum of 2 quarters · filed 2023-11-01 | $2.89M 10-Q · filed 2023-11-01 | -$1.04M derived: sum of 4 quarters · filed 2023-11-01 |
| 2022-06-30 | -$840.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | -$838.00K 10-Q · filed 2023-08-03 | -$4.77M derived: sum of 3 quarters · filed 2023-08-03 | -$262.00K derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | $2.00K 10-Q · filed 2023-05-08 | -$3.93M derived: sum of 2 quarters · filed 2023-05-08 | $578.00K derived: sum of 3 quarters · filed 2023-05-08 | $2.30M derived: sum of 4 quarters · filed 2023-05-08 |
| 2021-12-31 | -$3.93M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | $576.00K derived: sum of 2 quarters · filed 2023-03-15 | $2.30M derived: sum of 3 quarters · filed 2023-03-15 | $3.90M 10-K · filed 2023-03-15 |
| 2021-09-30 | $4.51M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $6.23M derived: sum of 2 quarters · filed 2022-11-14 | $7.83M 10-Q · filed 2022-11-14 | $7.06M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $1.73M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $3.33M 10-Q · filed 2022-08-09 | $2.55M derived: sum of 3 quarters · filed 2022-08-09 | $3.35M derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | $1.60M 10-Q · filed 2022-05-10 | $827.00K derived: sum of 2 quarters · filed 2022-05-10 | $1.62M derived: sum of 3 quarters · filed 2022-05-10 | $2.83M derived: sum of 4 quarters · filed 2022-05-10 |
| 2020-12-31 | -$774.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $23.00K derived: sum of 2 quarters · filed 2022-03-17 | $1.23M derived: sum of 3 quarters · filed 2022-03-17 | $1.16M 10-K · filed 2022-03-17 |
| 2020-09-30 | $797.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $2.00M derived: sum of 2 quarters · filed 2021-11-12 | $1.93M 10-Q · filed 2021-11-12 | $2.55M derived: sum of 4 quarters · filed 2021-11-12 |
| 2020-06-30 | $1.21M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $1.13M 10-Q · filed 2021-08-12 | $1.76M derived: sum of 3 quarters · filed 2021-08-12 | |
| 2020-03-31 | -$72.00K 10-Q · filed 2021-05-11 | $550.00K derived: sum of 2 quarters · filed 2021-05-11 | ||
| 2019-12-31 | $622.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-16 | $546.00K 10-K · filed 2021-03-16 | ||
| 2019-09-30 | -$76.00K 10-Q · filed 2020-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |